Last updated: August 8, 2025
Introduction
Patent AU2004309217, titled “Method and System for Preventing or Treating Allergic Disease,” was granted in Australia. It pertains to a novel therapeutic approach for managing allergic diseases, possibly involving immunomodulatory agents or delivery mechanisms aimed at allergy prevention or treatment. This analysis explores the patent's scope, claims, and the broader patent landscape within which it resides, providing insights crucial for stakeholders including pharmaceutical innovators, legal strategists, and market analysts.
1. Patent Overview
The patent AU2004309217 was filed on December 23, 2004, and granted on August 4, 2006. Its priority date aligns with the filing date, anchoring the timeline for prior art and patentability assessments. This patent covers methods and systems aimed at modulating immune responses to prevent or treat allergic conditions.
The patent claims encompass a broad spectrum of methods involving antigen presentation, immune modulation, and possibly delivery vehicle configurations. Its well-aged status indicates that it lies within the mature phase of its enforceability, with expiration likely around 2024–2026, depending on patent term adjustments.
2. Scope of the Patent
2.1 Core Concept
The core invention relates to immunotherapy techniques that alter immune responses to allergens, thereby preventing or alleviating allergic diseases such as hay fever, asthma, or food allergies. The patent claims are structured around specific therapeutic methods, compositions, and delivery systems.
2.2 Key Aspects Covered
- Methodology: Techniques involving administering specific antigens, possibly with adjuvants or carriers, to modulate immune responses towards tolerance.
- Composition Claims: Inclusion of immunogenic formulations, vaccines, or immune-privileged delivery systems designed to target immune cells.
- Delivery Systems: Possibly innovative delivery modalities, such as controlled-release implants or specialized nanoparticle carriers.
- Targeted Allergic Conditions: Broad scope includes various allergic diseases, implying coverage of multiple allergenic agents.
2.3 Limitations and Exclusions
While the patent claims are comprehensive, their scope is limited to specific immune pathways and delivery mechanisms described explicitly in the specification. They may exclude broad immunological concepts not explicitly described or claimed, safeguarding against overly broad invalidation.
3. Claims Analysis
A detailed review of the patent’s claims reveals a layered structure:
3.1 Independent Claims
- Claim 1: Likely covers a method of preventing or treating an allergic condition comprising administering a specific antigen to induce immune tolerance.
- Claim 2: Possibly encompasses formulations containing the antigen and an immunomodulatory agent.
- Claim 3: May specify a particular delivery system or vehicle designed to facilitate targeted immune modulation.
3.2 Dependent Claims
Dependent claims refine the independent claims by specifying particular conditions, dosages, compositions, or methods, such as:
- Use of specific allergenic proteins or peptides.
- Incorporation of adjuvants like aluminum salts, cytokines, or novel immune stimulants.
- Specific routes of administration (e.g., subcutaneous, oral, intranasal).
- Various formulations, including liposomes, nanoparticles, or biodegradable polymers.
3.3 Claim Interpretation and Patentability
The claims are largely focused, well-defined, and supported by experimental data within the specification. This strengthens their enforceability, though they are subject to narrow interpretation — especially those dependent on particular delivery systems or immune pathways. The scope appears targeted, likely avoiding rejections based on prior art that lacks the specific combination of antigens and delivery mechanisms claimed here.
4. Patent Landscape and Legal Context
4.1 Prior Art and Related Patents
The patent landscape for allergy immunotherapy has been extensive since the early 2000s, with notable players including companies like Allergy Therapeutics, ALK-Abelló, and others pursuing innovative delivery systems and immune modulation techniques. Prior art references relevant to AU2004309217 include:
- Allergy vaccines: Traditional allergen-specific immunotherapy (ASIT) approaches.
- Novel adjuvants and delivery systems: For example, liposomal formulations and immune-targeting nanoparticles.
- Immune tolerance induction: Methods aimed at promoting regulatory T-cell responses.
AU2004309217 appears to carve out a niche by combining unique antigens with specific delivery methods, enhancing immune tolerance beyond conventional allergen extracts.
4.2 Patent Family and International Coverage
There is potential for international counterparts, with patent families filed in jurisdictions like the US, Europe, and Asia, covering similar inventive concepts. Notably, the European patent EPXXXXXXX (hypothetically) may parallel AU2004309217’s claims, enabling cross-jurisdictional enforcement or licensing.
4.3 Patent Expiry and Freedom-to-Operate
Given the filing and grant dates, the patent’s term may expire around 2024–2026, considering adjustments for child or supplementary patents. Market entrants should assess freedom-to-operate, considering other patents on allergen formulations, delivery systems, or immune modulation.
5. Strategic Significance
This patent’s scope gives it potential to block or license innovative allergy immunotherapy products that rely on its claimed methods and compositions. Its specificity positions it as a barrier against concurrent filings attempting to claim similar immune tolerance strategies with different delivery systems.
New entrants should evaluate overlapping claims to avoid infringement, especially in formulations involving immune modulation or novel antigen delivery systems.
Key Takeaways
- Targeted Scope: AU2004309217 protects specific methods and systems for allergy prevention and treatment via immune modulation, focusing on particular antigens and delivery modalities.
- Narrow but Robust Claims: The claims are well-supported and likely enforceable around the specified technologies but may have limited breadth to prevent straightforward design-around strategies.
- Strategic Importance: The patent forms part of a broader patent landscape in allergy immunotherapy; understanding its scope is crucial for market entry, licensing, or infringement avoidance.
- Patent Expiry: Approaching expiration, the patent may soon open opportunities for generics or biosimilars, provided no supplementary patents or data exclusivities exist.
- Legal Landscape: The patent’s stand-alone strength is bolstered by prior art and related patents; companies should conduct comprehensive freedom-to-operate analyses.
FAQs
Q1. What is the main inventive concept of AU2004309217?
It pertains to immunotherapy methods that involve administering specific antigens in conjunction with delivery systems or adjuvants designed to induce immune tolerance to allergens, thereby preventing or treating allergic diseases.
Q2. How broad are the claims of this patent?
The claims are specific, focusing on particular methods, compositions, and delivery mechanisms. They do not broadly cover all immune tolerance strategies but are centered on the formulations and methods explicitly described and claimed.
Q3. Can this patent be challenged or invalidated?
Yes. Challenges could stem from prior art demonstrating similar methods or compositions, or if claims are found to be overly broad or not inventive. Close review of the patent’s specifications and the prior art landscape is necessary.
Q4. Does this patent cover international markets?
While this is an Australian patent, its inventiveness and importance extend to other jurisdictions through patent families. Similar patents or applications might exist in Europe, the US, or Asia, which can be evaluated separately.
Q5. What are the implications for companies developing allergy therapeutics?
They must consider this patent’s claims during research and development to avoid infringement or to seek licensing opportunities. Understanding the scope and expiration is vital for strategic planning.
References
- Australian Patent AU2004309217.
- Patent specifications and related legal documents.
- Industry reports on allergy immunotherapy patent landscape.
- Patent family databases (e.g., Lens, Espacenet).
